{"id":96920,"date":"2013-12-23T22:48:58","date_gmt":"2013-12-24T03:48:58","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/annals-of-internal-medicine-tip-sheet-for-dec-24-2013.php"},"modified":"2013-12-23T22:48:58","modified_gmt":"2013-12-24T03:48:58","slug":"annals-of-internal-medicine-tip-sheet-for-dec-24-2013","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/annals-of-internal-medicine-tip-sheet-for-dec-24-2013.php","title":{"rendered":"Annals of Internal Medicine tip sheet for Dec. 24, 2013"},"content":{"rendered":"<p><p>    PUBLIC RELEASE DATE:  <\/p>\n<p>    23-Dec-2013  <\/p>\n<p>    Contact: Megan Hanks    <a href=\"mailto:mhanks@acponline.org\">mhanks@acponline.org<\/a>    215-351-2656    American College of    Physicians<\/p>\n<p>    1. Unprecedented but Justified. Princeton meningitis    outbreak calls for \"compassionate use\" of unlicenced    vaccine  <\/p>\n<p>    In the wake of Princeton University's meningitis outbreak,    healthy individuals on campus who are at risk for infection    will be offered voluntary immunization with Bexsero (Novartis),    a vaccine that has not been approved for use in the United    States. Since March 22, 2013, health officials have confirmed    eight cases of Neisseria meningitides serogroup B (MenB)    meningitis among students and visitors at Princeton University.    Bexsero is the only vaccine in production that protects against    MenB. While the media have expressed concern about using an    \"experimental\" vaccine on students, the authors of an article    being published in Annals of Internal Medicine say    \"compassionate use\" of the unlicenced vaccine is justified    because epidemiologic evidence suggests that all Princeton    University meningitis cases are related and that transmission    is ongoing. They argue that the vaccine is not experimental, as    it has been approved for use in Europe and Australia. A plea    for broader access to the vaccine has been made by advocacy    groups, but the vaccine is being limited to Princeton    University students based upon policy and epidemiology. While    more than a third of total cases in the U.S. are due to MenB, a    monovalent MenB vaccine would need to be administered along    with the current quadrivalent conjugate meningococcal vaccine    to optimize protection against all of the serogroups that cause    the majority of disease in the U.S. The authors suggest that a    vaccine that prevents MenB still should be available in the    U.S. They write, \"our ability to mobilize resources in response    to this situation should compel us to take measures to ensure    access to this prevention tool with proven safety and efficacy    to all who are at risk.\" Full text of this article is available    at <a href=\"http:\/\/www.annals.org\/article.aspx?doi=10.7326\/M13-2927\" rel=\"nofollow\">http:\/\/www.annals.org\/article.aspx?doi=10.7326\/M13-2927<\/a>.  <\/p>\n<p>    Note: The URL may be included in coverage. Links go live at    5:00 p.m. on December 23. For an embargoed PDF, please contact    Megan Hanks or Angela Collom. To speak with an author, please    contact Dana Weidig at <a href=\"mailto:mortensen@email.chop.edu\">mortensen@email.chop.edu<\/a>    or 267-426-6092.  <\/p>\n<p>    2. Task Force recommends BRCA mutation screening for    high-risk women  <\/p>\n<p>    According to a new guideline being published in Annals of    Internal Medicine, the United States Preventive Services    Task Force (USPSTF) recommends that primary care providers    screen asymptomatic women with a family history of breast,    ovarian, tubal, or peritoneal cancers to determine if that    family history may be associated with an increased risk for    potentially harmful mutations in breast cancer susceptibility    genes BRCA1 or BRCA2. Women who screen positive should have    genetic counseling and, if indicated after counseling, BRCA    testing. The Task Force recommends against routine genetic    counseling or testing for average-risk women. The Task Force    identified specific screening tools that can be used in primary    care to guide referral to genetic counselors. In general, the    tools present a series of questions designed to elicit    information about factors associated with increased likelihood    of BRCA mutations. While the tools are all estimated to be more    than 85 percent sensitive, there was not enough evidence for    the Task Force to recommend one test over the other. This    recommendation is reaffirms the Task Force's 2005    recommendation on BRCA testing. The full recommendation is free    to the public and can be found at <a href=\"http:\/\/www.annals.org\/article.aspx?doi=10.7326\/M13-2747\" rel=\"nofollow\">http:\/\/www.annals.org\/article.aspx?doi=10.7326\/M13-2747<\/a>.  <\/p>\n<p>    Note: The URL may be included in coverage. Links go live at    5:00 p.m. on December 23. For an embargoed PDF, please contact    Megan Hanks or Angela Collom. To speak with a member of the    Task Force, please contact Nicole Raisch at <a href=\"mailto:nicole.raisch@edelman.com\">nicole.raisch@edelman.com<\/a>    or 202-572-2044.  <\/p>\n<p>    3. The American College of Physicians explains how Medicaid    expansion will help the poor  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Here is the original post:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2013-12\/acop-enf121813.php\" title=\"Annals of Internal Medicine tip sheet for Dec. 24, 2013\">Annals of Internal Medicine tip sheet for Dec. 24, 2013<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PUBLIC RELEASE DATE: 23-Dec-2013 Contact: Megan Hanks <a href=\"mailto:mhanks@acponline.org\">mhanks@acponline.org<\/a> 215-351-2656 American College of Physicians 1. Unprecedented but Justified. Princeton meningitis outbreak calls for \"compassionate use\" of unlicenced vaccine In the wake of Princeton University's meningitis outbreak, healthy individuals on campus who are at risk for infection will be offered voluntary immunization with Bexsero (Novartis), a vaccine that has not been approved for use in the United States <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/annals-of-internal-medicine-tip-sheet-for-dec-24-2013.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-96920","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/96920"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=96920"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/96920\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=96920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=96920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=96920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}